A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 05 Apr 2018 Planned number of patients changed to 180.
- 21 Mar 2018 Planned number of patients changed from 210to 152.
- 21 Mar 2018 Status changed from recruiting to active, no longer recruiting.